At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
In Brief
A Phase 2 clinical trial evaluating PF-04965842 and Placebo for Atopic Dermatitis. Completed, enrolled 269 participants across 64 sites in 5 countries.
Detailed Summary
Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstrate the efficacy of PF 04965842 by showing improvement in disease severity in patients with moderate to severe AD as measured by the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) scores, and safety to support further clinical development of PF 04965842.
Study Details
Timeline
Interventions
10 mg of PF-04965842 QD for 12 weeks
30 mg of PF-04965842 QD for 12 weeks
100 mg of PF-04965842 QD for 12 weeks
200 mg of PF-04965842 QD for 12 weeks
Placebo QD for 12 weeks